Heatwurx (NASDAQ:PCSA) Posts Earnings Results

Heatwurx (NASDAQ:PCSA) announced its earnings results on Friday. The company reported ($1.19) earnings per share for the quarter, Zacks reports.

Heatwurx Stock Performance

PCSA traded down $0.07 during trading on Friday, hitting $2.43. The stock had a trading volume of 49,930 shares, compared to its average volume of 647,212. The firm has a market capitalization of $6.73 million, a P/E ratio of -0.26 and a beta of 0.99. The company’s 50-day moving average price is $2.23 and its 200 day moving average price is $2.50. Heatwurx has a twelve month low of $1.67 and a twelve month high of $14.24.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $25.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.